These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 30877679)

  • 61. Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide.
    Muzzi A; Brozzi A; Serino L; Bodini M; Abad R; Caugant D; Comanducci M; Lemos AP; Gorla MC; Křížová P; Mikula C; Mulhall R; Nissen M; Nohynek H; Simões MJ; Skoczyńska A; Stefanelli P; Taha MK; Toropainen M; Tzanakaki G; Vadivelu-Pechai K; Watson P; Vazquez JA; Rajam G; Rappuoli R; Borrow R; Medini D
    Vaccine; 2019 Feb; 37(7):991-1000. PubMed ID: 30661831
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen.
    Seib KL; Scarselli M; Comanducci M; Toneatto D; Masignani V
    Expert Rev Vaccines; 2015 Jun; 14(6):841-59. PubMed ID: 25704037
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment.
    Vogel U; Taha MK; Vazquez JA; Findlow J; Claus H; Stefanelli P; Caugant DA; Kriz P; Abad R; Bambini S; Carannante A; Deghmane AE; Fazio C; Frosch M; Frosi G; Gilchrist S; Giuliani MM; Hong E; Ledroit M; Lovaglio PG; Lucidarme J; Musilek M; Muzzi A; Oksnes J; Rigat F; Orlandi L; Stella M; Thompson D; Pizza M; Rappuoli R; Serruto D; Comanducci M; Boccadifuoco G; Donnelly JJ; Medini D; Borrow R
    Lancet Infect Dis; 2013 May; 13(5):416-25. PubMed ID: 23414709
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination.
    Carter NJ
    BioDrugs; 2013 Jun; 27(3):263-74. PubMed ID: 23575646
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Potential impact of the 4CMenB vaccine on oropharyngeal carriage of Neisseria meningitidis.
    Abad R; Medina V; Fariñas MDC; Martínez-Martínez L; Bambini S; Dari A; Medini D; Pizza M; Vázquez JA
    J Infect; 2017 Dec; 75(6):511-520. PubMed ID: 28987549
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Invasive serogroup B meningococci in England following three years of 4CMenB vaccination - First real-world data.
    Lucidarme J; Bai X; Lekshmi A; Clark SA; Willerton L; Ribeiro S; Campbell H; Serino L; De Paola R; Holland A; Louth J; Ramsay ME; Ladhani SN; Borrow R
    J Infect; 2022 Feb; 84(2):136-144. PubMed ID: 34838814
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.
    Su EL; Snape MD
    Expert Rev Vaccines; 2011 May; 10(5):575-88. PubMed ID: 21604979
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans.
    Toneatto D; Ismaili S; Ypma E; Vienken K; Oster P; Dull P
    Hum Vaccin; 2011 Jun; 7(6):646-53. PubMed ID: 21904120
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac.
    Findlow J; Taylor S; Aase A; Horton R; Heyderman R; Southern J; Andrews N; Barchha R; Harrison E; Lowe A; Boxer E; Heaton C; Balmer P; Kaczmarski E; Oster P; Gorringe A; Borrow R; Miller E
    Infect Immun; 2006 Aug; 74(8):4557-65. PubMed ID: 16861642
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Serogroup B Meningococcal Vaccine Bexsero Elicits Antibodies to Neisseria gonorrhoeae.
    Semchenko EA; Tan A; Borrow R; Seib KL
    Clin Infect Dis; 2019 Sep; 69(7):1101-1111. PubMed ID: 30551148
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Predicted vs observed effectiveness of outer membrane vesicle (OMV) vaccines against meningococcal serogroup B disease: Systematic review.
    Harder T; Koch J; Wichmann O; Hellenbrand W
    J Infect; 2017 Aug; 75(2):81-94. PubMed ID: 28487177
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae.
    Leduc I; Connolly KL; Begum A; Underwood K; Darnell S; Shafer WM; Balthazar JT; Macintyre AN; Sempowski GD; Duncan JA; Little MB; Rahman N; Garges EC; Jerse AE
    PLoS Pathog; 2020 Dec; 16(12):e1008602. PubMed ID: 33290434
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Molecular characterization of invasive serogroup B Neisseria meningitidis isolates from Spain during 2015-2018: Evolution of the vaccine antigen factor H binding protein (FHbp).
    Abad R; García-Amil C; Navarro C; Martín E; Martín-Díaz A; Vázquez JA
    J Infect; 2021 Apr; 82(4):37-44. PubMed ID: 33610688
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy.
    Fazio C; Biolchi A; Neri A; Tomei S; Vacca P; Ambrosio L; Palmieri A; Mori E; La Gaetana R; Pizza M; Giuliani MM; Serino L; Stefanelli P
    Hum Vaccin Immunother; 2021 Jul; 17(7):2225-2231. PubMed ID: 33522380
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Capsule null locus meningococci: typing of antigens used in an investigational multicomponent meningococcus serogroup B vaccine.
    Claus H; Jördens MS; Kriz P; Musilek M; Jarva H; Pawlik MC; Meri S; Vogel U
    Vaccine; 2012 Jan; 30(2):155-60. PubMed ID: 22107847
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [From a pathogen's genome to an effective vaccine: the four-component meningococcal serogroup B vaccine].
    Abad R; Martinón-Torres F; Santolaya ME; Banzhoff A; González-Inchausti C; Graña MG; Vázquez JA
    Rev Esp Quimioter; 2019 Jun; 32(3):208-216. PubMed ID: 31148440
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine.
    Vermont CL; van Dijken HH; Kuipers AJ; van Limpt CJ; Keijzers WC; van der Ende A; de Groot R; van Alphen L; van den Dobbelsteen GP
    Infect Immun; 2003 Apr; 71(4):1650-5. PubMed ID: 12654777
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The use of vaccine antigen characterization, for example by MATS, to guide the introduction of meningococcus B vaccines.
    Vogel U; Stefanelli P; Vazquez J; Taha MK; Claus H; Donnelly J
    Vaccine; 2012 May; 30 Suppl 2():B73-7. PubMed ID: 22607902
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study.
    Santolaya ME; O'Ryan ML; Valenzuela MT; Prado V; Vergara R; Muñoz A; Toneatto D; Graña G; Wang H; Clemens R; Dull PM;
    Lancet; 2012 Feb; 379(9816):617-24. PubMed ID: 22260988
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Molecular typing of group B Neisseria meningitidis'subcapsular antigens directly on biological samples demonstrates epidemiological congruence between culture-positive and -negative cases: A surveillance study of invasive disease over a 13-year period.
    Lodi L; Moriondo M; Nieddu F; Ricci S; Guiducci S; Lippi F; Canessa C; Calistri E; Citera F; Giovannini M; Indolfi G; Resti M; Azzari C
    J Infect; 2021 Apr; 82(4):28-36. PubMed ID: 33610687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.